In Vivo's Deals Of The Month, September 2017
In Vivo's editors pick September's most significant deals, including lucrative partnerships for Halozyme and the pursuit of Dimension Therapeutics. (Free article.)
You may also be interested in...
ProQR spinout Amylon gets started by licensing four central nervous system disorder candidates from its parent, while start-up Eyevance gets US rights to Nicox’s Zerviate.
No disease is too small or too large for SpringWorks, which spun out Pfizer with four mid-/late-stage compounds to develop drugs in indications where patients have no good treatment options.
Bristol will pay $105m up front and as much as $1.76bn in milestone fees to use the Enhanze technology in drugs against up to 11 immuno-oncology targets. Also, Roche will pay up to $190m to add a target to an existing partnership.